20xx年醫(yī)學(xué)專題—冠狀動(dòng)脈無(wú)復(fù)流現(xiàn)象的防治-資料下載頁(yè)
2024-11-05 00:16本頁(yè)面
【正文】 237。jiē)支架植入,A Randomized Comparison of Direct Stenting With Conventional Stent Implantation in Selected Patients With Acute Myocardial Infarction AMI直接(zh237。jiē)支架植入和傳統(tǒng)支架植入的隨機(jī)對(duì)照研究,J Am Coll Cardiol 2002。39:15–21,第七十一頁(yè)，共八十六頁(yè)。,randomized, singlecenter trial 206 were allocated to direct stent implantation (n=102) or stent implantation after balloon predilation (n=104),J Am Coll Cardiol 2002。39:15–21,第七十二頁(yè)，共八十六頁(yè)。,J Am Coll Cardiol 2002。39:15–21,第七十三頁(yè)，共八十六頁(yè)。,J Am Coll Cardiol 2002。39:15–21,兩組住院(zh249。 yu224。n)期間的臨床結(jié)果,第七十四頁(yè)，共八十六頁(yè)。,準(zhǔn)分子激光(jīguāng)消栓,Excimer laser thrombus elimination for prevention of distal embolization and noreflow in patients with acute ST elevation myocardial infarction Results from the randomized Laser AMI study 27 consecutive patients with STsegment elevation AMI (aged 57.8177。9.2 years) were randomized either to balloon angioplasty and stent implantation alone (n=13) or adjunct ELCA (n=14).,International Journal of Cardiology 116 (2007) 20–26,第七十五頁(yè)，共八十六頁(yè)。,ELCA was feasible and safe in all cases. No procedureassociated complications were observed.,International Journal of Cardiology 116 (2007) 20–26,P0.05,第七十六頁(yè)，共八十六頁(yè)。,International Journal of Cardiology 116 (2007) 20–26,第七十七頁(yè)，共八十六頁(yè)。,International Journal of Cardiology 116 (2007) 20–26,第七十八頁(yè)，共八十六頁(yè)。,治療(zh236。li225。o),硝酸甘油（Nitroglycerin） 腺苷（Adenosine） 尼可地爾(KATP通道(tōngd224。o)開(kāi)放劑)（Nicorandil） 維拉帕米（Verapamil） 地爾硫卓（Diltiazem） 硝普鈉（Sodium Nitroprusside） 烏拉地爾（Urapidil） GP IIb/IIIa受體拮抗劑（GP IIb/IIIa receptor antagonist）,第七十九頁(yè)，共八十六頁(yè)。,Intracoronary Verapamil for Reversal of NoReflow During Coronary Angioplasty for Acute Myocardial Infarction 冠脈內(nèi)給予(jǐyǔ)維拉帕米逆轉(zhuǎn)AMI冠狀動(dòng)脈成形術(shù)中無(wú)復(fù)流,Cathet Cardiovasc Intervent 002。57:444–451.,第八十頁(yè)，共八十六頁(yè)。,a consecutive series of 212 direct or rescue PTCAs for AMI，a TIMI flow grade 3 was observed in 23 patients (10.8%) Ten of the 23 patients had received GP IIb/IIIa antagonists before PTCA,Cathet Cardiovasc Intervent 002。57:444–451.,第八十一頁(yè)，共八十六頁(yè)。,A：LAD閉塞(b236。s232。)，B：球囊擴(kuò)張后TIMI2級(jí)血流，C：支架植入后無(wú)血流，D：沿導(dǎo)絲送入灌注導(dǎo)管至支架遠(yuǎn)端，注入維拉帕米1mg，E：保留灌注導(dǎo)管造影TIMI3級(jí)，F(xiàn)：15MIN后造影,Cathet Cardiovasc Intervent 002。57:444–451.,第八十二頁(yè)，共八十六頁(yè)。,Individual changes of TFC in 23 patients with noreflow after intracoronary verapamil. The significant change of group mean standard deviation is also shown (P 0.001).,Cathet Cardiovasc Intervent 002。57:444–451.,第八十三頁(yè)，共八十六頁(yè)。,Cathet Cardiovasc Intervent 002。57:444–451.,第八十四頁(yè)，共八十六頁(yè)。,腺甘和鈣桔抗劑的實(shí)驗(yàn)(sh237。y224。n)對(duì)比研究,Cardiovasc Drugs Ther (2006) 20: 167–175,結(jié)扎區(qū)域(qūy249。) (LA)，無(wú)復(fù)流區(qū)域 (ANR)，壞死區(qū)域 (NA) Histopathological 組織病理學(xué),第八十五頁(yè)，共八十六頁(yè)。,內(nèi)容(n232。ir243。ng)總結(jié),冠狀動(dòng)脈無(wú)復(fù)流現(xiàn)象的防治。無(wú)復(fù)流區(qū)面積隨再灌注時(shí)間延長(zhǎng)而增加，部分無(wú)復(fù)流可發(fā)生于再灌注后的248小時(shí)。應(yīng)用壓力導(dǎo)絲測(cè)量靶動(dòng)脈的壓力階差，并計(jì)算心肌(xīnjī)血流儲(chǔ)備分?jǐn)?shù)(FFRmyo)。遠(yuǎn)端保護(hù)/血栓抽吸裝置（主要用于橋血管PCI和AMI直接PCI）。Histopathological 組織病理學(xué),第八十六頁(yè)，共八十
畢業(yè)設(shè)計(jì)相關(guān)推薦
鄂ICP備17016276號(hào)-1